PT - JOURNAL ARTICLE AU - Yeoh, Sophya AU - Estrada-Rivadeneyra, Diego AU - Jackson, Heather AU - Keren, Ilana AU - Galassini, Rachel AU - Cooray, Samantha AU - Shah, Priyen AU - Agyeman, Philipp AU - Basmaci, Romain AU - Carrol, Enitan AU - Emonts, Marieke AU - Fink, Colin AU - Kuijpers, Taco AU - Torres, Federico Martinon- AU - Mommert-Tripon, Marine AU - Paulus, Stephane AU - Pokorn, Marko AU - Rojo, Pablo AU - Romani, Lorenza AU - Schlapbach, Luregn AU - Schweintzger, Nina AU - Shen, Ching-Fen AU - Tsolia, Maria AU - Usuf, Effua AU - Van der Flier, Michiel AU - Vermont, Clementien AU - Both, Ulrich Von AU - Yeung, Shunmay AU - Zavadska, Dace AU - Coin, Lachlan AU - Cunnington, Aubrey AU - Herberg, Jethro AU - Levin, Michael AU - Kaforou, Myrsini AU - Hamilton, Shea AU - , AU - , TI - Plasma protein biomarkers distinguish Multisystem Inflammatory Syndrome in Children (MIS-C) from other pediatric infectious and inflammatory diseases AID - 10.1101/2023.07.28.23293197 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.28.23293197 4099 - http://medrxiv.org/content/early/2023/07/31/2023.07.28.23293197.short 4100 - http://medrxiv.org/content/early/2023/07/31/2023.07.28.23293197.full AB - Background Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious hyperinflammatory complication following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanisms underpinning the pathophysiology of MIS-C are poorly understood. Moreover, clinically distinguishing MIS-C from other childhood infectious and inflammatory conditions, such as Kawasaki Disease (KD) or severe bacterial and viral infections is challenging due to overlapping clinical and laboratory features. We aimed to determine a set of plasma protein biomarkers that could discriminate MIS-C from those other diseases.Methods Seven candidate protein biomarkers for MIS-C were selected based on literature and from whole blood RNA-Sequencing data from patients with MIS-C and other diseases. Plasma concentrations of ARG1, CCL20, CD163, CORIN, CXCL9, PCSK9 and ADAMTS2 were quantified in MIS-C (n=22), KD (n=23), definite bacterial (DB; n=28) and viral (DV, n=27) disease, and healthy controls (n=8). Logistic regression models were used to determine the discriminatory ability of individual proteins and protein combinations to identify MIS-C, and association with severity of illness.Results Plasma levels of CD163, CXCL9, and PCSK9 were significantly elevated in MIS-C with a combined AUC of 86% (95% CI: 76.8%-95.1%) for discriminating MIS-C from other childhood diseases. Lower ARG1 and CORIN plasma levels were significantly associated with severe MIS-C cases requiring oxygen, inotropes or with shock.Conclusion Our findings demonstrate the feasibility of a host protein biomarker signature for MIS-C and may provide new insight into its pathophysiology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the European Union’s Horizon 2020 Program under grants (848196 DIAMONDS, 668303 PERFORM) and the UK National Institute for Health Research Imperial Biomedical Research Centre at Imperial College (WMNP_P69099), the Javon Charitable Trust and the Children of St Mary's Intensive Care Kawasaki Disease Research Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was taken from all patients recruited to the study. Recruitment at all locations took place after ethical permissions were in place for that area. In the DIAMONDS study (Diagnosis and Management of Febrile Illness using RNA Personalized Molecular Signature Diagnosis https://www.diamonds2020.eu) and the PERFORM study (Personalized Risk assessment in Febrile illness to Optimize Real-life Management, perform2020.org/), the consortium agreed on a finalized protocol and supporting documents that were translated into local languages. Each participating country took responsibility for gaining ethical approval in their region. For DIAMONDS, the lead site received ethical approval for United Kingdom centers from the London-Dulwich research ethics committee (20/HRA/1714). For the PERFORM study, the lead site received approval ethical approval for United Kingdom centers from the London-Central research ethics committee (16/LO/1684). The Genetic Determinants of Kawasaki Disease for Susceptibility and Outcome study recruited in the United Kingdom only, and ethical approval was granted by the London-Fulham research ethics committee (13/LO/0026). During the conduct of the study, clinical data and samples were identified only by anonymized study numbers.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.